Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

Phase 3

Withdrawn

Conditions: Leukemia

First Posted Date: 2004-02-27

Last Posted Date: 2012-03-23

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00019409

Locations: 🇮🇳
Tata Memorial Centre, Mumbai, India
🇮🇳
Cancer Institute (W.I.A.), Madras, India
🇮🇳
All-India Institute of Medical Sciences, New Delhi, India

and more 3 locations

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

Phase 3

Conditions: Carcinoma of Unknown Primary

First Posted Date: 2004-02-27

Last Posted Date: 2013-09-20

Lead Sponsor: The Christie NHS Foundation Trust

Registration Number: NCT00022178

Locations: 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

Phase 1

Completed

Conditions: Breast Cancer
Leukemia
Lymphoma
Neuroblastoma
Ovarian Cancer
Sarcoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-02-20

Last Posted Date: 2013-04-26

Lead Sponsor: University of Kentucky

Target Recruit Count: 25

Registration Number: NCT00003425

Locations: 🇺🇸
Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

Phase 2

Completed

Conditions: Brain Tumors
Central Nervous System Tumors

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-02-20

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 53

Registration Number: NCT00003573

Locations: 🇺🇸
Hope Children's Hospital, Oak Lawn, Illinois, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Saint Jude Midwest Affiliate, Peoria, Illinois, United States

and more 103 locations

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-02-16

Last Posted Date: 2013-06-21

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 630

Registration Number: NCT00003150

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States

and more 88 locations

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-02-16

Last Posted Date: 2017-01-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 71

Registration Number: NCT00005089

Locations: 🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 89 locations

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation